As of March 31, 2023, there were 1,528,077 shares available under the 2017 Plan including shares that were forfeited under the prior plans for future issuance.

On December 15, 2021, the Company’s stockholders approved an amendment (the “Plan Amendment”) to the 2017 Plan, which (i) increased the number of shares of Common Stock available for grant under the Plan by 1,500,000 additional shares of Common Stock and (ii) allows the Company to utilize awards to attract and incentivize non-employee consultants.

One-third of the total number of shares subject to each stock option vest ratably on each of the first three anniversaries of the grant date, contingent on continued employment, and subject to accelerated vesting in certain circumstances. There were no NQOs granted during the nine months ended March 31, 2023.


Outstanding NQOs:	Number of NQOs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2022	450,687	12.39	4.34	$	—
Granted	—	—	—	—
Exercised	—	—	—	—
Cancelled/Forfeited	(21,926)	11.92	—	—
Expired	(35,174)	18.99	—	—
Outstanding at March 31, 2023	393,587	11.83	3.05	$	—
Exercisable at March 31, 2023	363,498	12.25	2.98	$	—

The aggregate intrinsic values outstanding at the end of period in the table above represent the total pretax intrinsic values, based on the closing price of Common Stock of $3.86 and $4.69 at March 31, 2023 and June 30, 2022, respectively, representing the last trading day of the respective periods, which would have been received by NQO holders had all award holders exercised their NQOs that were in-the-money as of those dates. NQOs outstanding that are expected to vest are net of estimated forfeitures.

At March 31, 2023 and June 30, 2022, respectively, there was $6 thousand and $0.2 million of unrecognized NQO compensation cost. The unrecognized NQO compensation cost at March 31, 2023 is expected to be recognized over the weighted average period of one month. Total compensation expense for NQOs was $5 thousand and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Total compensation expense for NQOs was $0.1 million and $0.4 million for the nine months ended March 31, 2023 and 2022, respectively.


Outstanding PNQs:	Number of PNQs	Weighted Average Exercise Price ($)	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value ($ in thousands)
Outstanding at June 30, 2022	2,212	30.91	0.83	$	—
Granted	—	—	—	—
Exercised	—	—	—	—
Cancelled/Forfeited	—	—	—	—
Expired	(1,221)	29.48	—	—
Outstanding at March 31, 2023	991	32.84	0.61	$	—
Exercisable at March 31, 2023	991	32.85	0.61	$	—

The aggregate intrinsic values outstanding at the end of each fiscal period in the table above represent the total pretax intrinsic values, based on the Company’s closing stock price of $3.86 and $4.69 at March 31, 2023 and June 30, 2022, respectively, representing the last trading day of the respective fiscal periods, which would have been received by PNQ holders had all award holders exercised their PNQs that were in-the-money as of those dates.

At March 31, 2023 and June 30, 2022, there was no unrecognized PNQ compensation cost. There was no compensation expense related to PNQs in the three and nine months ended March 31, 2023 and 2022.


Outstanding and Nonvested Restricted Stock Awards:	Shares Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2022	816,811	6.67
Granted	680,579	5.68
Vested/Released	(312,925)	6.70
Cancelled/Forfeited	(226,437)	6.55
Outstanding and nonvested at March 31, 2023	958,028	6.11

The weighted average grant date fair value of RSUs granted during the quarters ended March 31, 2023 and 2022 were $5.68 and $8.18, respectively. The total grant-date fair value of restricted stock granted during the nine months ended March 31, 2023 was $4.0 million. The total fair value of awards vested during the nine months ended March 31, 2023 and 2022 were $1.6 million and $2.2 million, respectively.

At March 31, 2023 and June 30, 2022, there was $4.4 million and $3.9 million, respectively, of unrecognized compensation cost related to restricted stock. The unrecognized compensation cost related to restricted stock at March 31, 2023 is expected to be recognized over the weighted average period of 1.9 years. Total compensation expense for restricted stock was $0.5 million and $0.5 million, respectively, in the three months ended March 31, 2023 and 2022. Total compensation expense for restricted stock was $1.9 million and $1.5 million, respectively, in the nine months ended March 31, 2023 and 2022.


Outstanding and Nonvested PBRSUs:	PBRSUs Awarded (1)	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2022	456,993	6.16
Granted (1)	214,842	6.40
Vested/Released	—	—
Cancelled/Forfeited	(122,544)	7.64
Outstanding and nonvested at March 31, 2023	549,291	5.92

(1) The target number of PBRSUs is presented in the table. Under the terms of the awards, the recipient may earn between 0% and 200% of the target number of PBRSUs depending on the extent to which the Company meets or exceeds the achievement of the applicable financial performance goals.

The weighted average grant date fair value of PBRSUs granted during the quarters ended March 31, 2023 and 2022 were $6.40 and $8.91, respectively. The total grant-date fair value of PBRSUs granted during the nine months ended March 31, 2023 was $1.4 million. The total fair value of awards vested during the nine months ended March 31, 2022 were $3 thousand.

At March 31, 2023 and June 30, 2022, there was $1.9 million and $1.7 million, respectively, of unrecognized PBRSU compensation cost. The unrecognized PBRSU compensation cost at March 31, 2023 is expected to be recognized over the weighted average period of 1.9 years. Total compensation expense for PBRSUs was $0.1 million and $0.2 million, respectively, for the three months ended March 31, 2023 and 2022. Total compensation expense for PBRSUs was $0.5 million and $0.5 million, respectively, for the nine months ended March 31, 2023 and 2022.

CSRSUs vest in equal installments over a three-year period from the grant date, and are cash-settled upon vesting based on the closing share price of Common Stock on the vesting date.

The CSRSUs are accounted for as liability awards, and compensation expense is measured at fair value on the date of grant and recognized on a straight-line basis over the vesting period net of forfeitures. Compensation expense is remeasured at each reporting date with a cumulative adjustment to compensation cost during the period based on changes in the closing share price of Common Stock.


Outstanding and Nonvested CSRSUs:	CSRSUs Awarded	Weighted Average Grant Date Fair Value ($)
Outstanding and nonvested at June 30, 2022	145,645	6.36
Granted	178,099	6.40
Vested/Released	(42,670)	6.24
Cancelled/Forfeited	(90,685)	6.26
Outstanding and nonvested at March 31, 2023	190,389	6.47

The weighted average grant date fair value of CSRSUs granted during the quarters ended March 31, 2023 and 2022 were $6.40 and $8.91, respectively. The total grant-date fair value of CSRSUs granted during the nine months ended March 31, 2023 was $1.1 million. The total fair value of awards vested during the nine months ended March 31, 2023 and 2022 was $0.2 million and $0.4 million, respectively.